
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

**POST-EFFECTIVE AMENDMENT NO. 1
TO
FORM S-8
REGISTRATION STATEMENT (FILE NO. 333-81009)
UNDER
THE SECURITIES ACT OF 1933**

Nabi Biopharmaceuticals

(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

59-1212264
(I.R.S. Employer
Identification No.)

12276 Wilkins Avenue
Rockville, MD 20852
(301)770-3099
(Address, including zip code, and telephone number, including
area code, of registrant's principal executive offices)

Rafaat E.F. Fahim
Chief Executive Officer and President
Nabi Biopharmaceuticals
12276 Wilkins Avenue
Rockville, MD 20852
(301)770-3099
(Name, address, including zip code, and telephone number,
including area code, of agent for service)

Copy to:
James E. Dawson, Esq.
Nutter, McClennen & Fish, LLP
155 Seaport Boulevard
Boston, MA 02210
(617) 439-2000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company)

Smaller reporting company

Deregistration of Unsold Securities

Pursuant to Registration Statement on Form S-8 (File No. 333-81009) (the "Registration Statement") filed with the Securities and Exchange Commission (the "SEC") on June 18, 1999 by Nabi Biopharmaceuticals (the "Company"), the Company registered 150,000 shares (the "Securities") of the Company's common stock, par value \$.10 per share (the "Securities"), issuable pursuant to its Stock Plan for Non-Employee Directors (the "Plan"). The Company has ceased issuing Securities under the Plan.

The Company seeks to deregister the Securities that remain unissued under the Registration Statement as of the date hereof. Pursuant to the undertaking of the Company contained in the Registration Statement pursuant to Item 512(a)(3) of Regulation S-K, the Company is filing this Post-Effective Amendment No. 1 to the Registration Statement to deregister the Securities remaining unissued under the Registration Statement.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Rockville, State of Maryland, on the 22nd day of May, 2009.

NABI BIOPHARMACEUTICALS

By: /s/ Raafat E.F. Fahim, Ph.D.
Raafat E.F. Fahim, Ph.D.
President and Chief Executive Officer

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints Raafat Fahim and James E. Dawson, and each of them, with full power to act without the others, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for the undersigned and in his or her name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective amendments) to this registration statement and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing necessary or advisable to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933 this Post-Effective Amendment No. 1 to the Registration Statement has been signed by the following persons in the capacities indicated, as of May 22, 2009.

<u>Signatures</u>	<u>Title</u>
<u>/s/ Raafat E.F. Fahim, Ph.D</u> Raafat E.F. Fahim, Ph.D	President, Chief Executive Officer, acting Chief Financial Officer and Director
<u>/s/ Ronald B. Kocak</u> Ronald B. Kocak	Corporate Controller and Chief Accounting Officer
<u>/s/ Geoffrey F. Cox, Ph.D.</u> Geoffrey F. Cox, Ph.D.	Chairman of the Board
<u>/s/ Jason Aryeh</u> Jason Aryeh	Director
<u>/s/ David L. Castaldi</u> David L. Castaldi	Director
<u>/s/ Peter B. Davis</u> Peter B. Davis	Director
<u>/s/ Richard A. Harvey, Jr.</u> Richard A. Harvey, Jr.	Director
<u>/s/ Linda Jenckes</u> Linda Jenckes	Director
<u>/s/ Timothy Lynch</u> Timothy Lynch	Director
<u>/s/ Stephen G. Sudovar</u> Stephen G. Sudovar	Director